2595 Stock Chart & Stats
HK$45.54
--
Market closed
HK$45.54
--
Day’s Range― - ―
52-Week RangeHK$19.60 - HK$52.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.12M
Market Cap
HK$10.65B
Enterprise ValueHK$6.61K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.24
Shares Outstanding351,629,030
10 Day Avg. Volume1,088,501
30 Day Avg. Volume3,122,091
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$56.18Price Target Upside23.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.39
Revenue Forecast (FY)HK$98.62M
Genfleet Therapeutics (Shanghai), Inc. Class H News
2595 FAQ
What was Genfleet Therapeutics (Shanghai), Inc. Class H’s price range in the past 12 months?
Genfleet Therapeutics (Shanghai), Inc. Class H lowest stock price was HK$19.60 and its highest was HK$52.90 in the past 12 months.
What is Genfleet Therapeutics (Shanghai), Inc. Class H’s market cap?
Genfleet Therapeutics (Shanghai), Inc. Class H’s market cap is HK$10.65B.
When is Genfleet Therapeutics (Shanghai), Inc. Class H’s upcoming earnings report date?
Genfleet Therapeutics (Shanghai), Inc. Class H’s upcoming earnings report date is Aug 21, 2026 which is in 14 days.
How were Genfleet Therapeutics (Shanghai), Inc. Class H’s earnings last quarter?
Genfleet Therapeutics (Shanghai), Inc. Class H released its earnings results on Mar 24, 2026. The company reported -HK$3.239 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Genfleet Therapeutics (Shanghai), Inc. Class H overvalued?
According to Wall Street analysts Genfleet Therapeutics (Shanghai), Inc. Class H’s price is currently Undervalued.
Does Genfleet Therapeutics (Shanghai), Inc. Class H pay dividends?
Genfleet Therapeutics (Shanghai), Inc. Class H does not currently pay dividends.
What is Genfleet Therapeutics (Shanghai), Inc. Class H’s EPS estimate?
Genfleet Therapeutics (Shanghai), Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genfleet Therapeutics (Shanghai), Inc. Class H have?
Genfleet Therapeutics (Shanghai), Inc. Class H has 351,629,030 shares outstanding.
What happened to Genfleet Therapeutics (Shanghai), Inc. Class H’s price movement after its last earnings report?
Genfleet Therapeutics (Shanghai), Inc. Class H reported an EPS of -HK$3.239 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.879%.
Which hedge fund is a major shareholder of Genfleet Therapeutics (Shanghai), Inc. Class H?
Currently, no hedge funds are holding shares in HK:2595
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genfleet Therapeutics (Shanghai), Inc. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$56.18 (23.36% Upside)
HK$56.18 (23.36% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
278.68%
Trailing 12-Months
Company Description
Genfleet Therapeutics (Shanghai), Inc. Class H
GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases in the United States. The company develops GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C in a Phase III trial for the treatment of pancreatic cancer, as well as in Phase II trials for the treatment of non-small cell lung cancer (NSCLC) and BTC, and in a Phase I trial for the treatment of solid tumors; GFH925, a small molecule selective inhibitor of KRAS G12C in a Phase II trial for the treatment of advanced NSCLC; and GFH009, a highly selective cyclin-dependent kinase (CDK) 9 inhibitor in a Phase II trial for the treatment of AML. It is also developing GFH276, a pan-RAS inhibitor in a Phase I trial for the treatment of solid tumors; GFS202A, a bispecific antibody in a Phase I trial for the treatment of cachexia; GFH312, a receptor-interacting serine/threonine-protein kinase (RIPK) 1 inhibitor in a Phase I clinical trial for the treatment of PAD with IC and PBC; GFS784, a pan-RAS antibody drug conjugate (ADC) candidate with an IND application for the treatment of solid tumors; and GFH946, an oral PROTAC product candidate with an IND application for the treatment of type 2 inflammation. In addition, the company offers technical services. It has collaboration agreements with Merck Healthcare KGaA for trials of combinational regimens, including cetuximab; Verastem, Inc. to develop and commercialize GFH375; and SELLAS Life Sciences Group, Inc. to develop, manufacture, and commercialize GFH009. GenFleet Therapeutics (Shanghai) Inc. was incorporated in 2017 and is headquartered in Shanghai, China.
2595 Stock 12 Month Forecast
Average Price Target
HK$56.18
▲(23.36% Upside)
Technical Analysis
Antengene Corporation Limited
―
Kintor Pharmaceutical Ltd
―
CANbridge Pharmaceuticals Inc.
―
Sirnaomics Ltd.
―
Transcenta Holding Limited
―